Why the study?
Chemotherapies, especially anthracyclines, cause drug-related cardiomyopathy leading to heart failure and impaired survival in cancer patients.
What is the best pharmacological approach for primary prevention of chemotherapy-induced cardiomyopathy in oncologic patients?
What is the best pharmacological approach for primary prevention of chemotherapy-induced cardiomyopathy in oncologic patients?
This paper reviews pharmacological strategies for the primary prevention of chemotherapy-induced cardiomyopathy, particularly related to anthracyclines.
Answers are grounded in this paper and cite their sources.
Anthracycline cardiomyopathy surveillance remains essential in cancer survivors; Level 5 data leave optimal prevention strategies open.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Ávila et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: